atezolizumab
roche
['platform', 'imvigor130']
the indefatigable compares pd-l1 assay (sp142 vs dako 22c3 clones) in #imvigor130 trial. the platforms select for different patients sp142 staining co-localised dcs / t-cells sp142 has better prognostic ability
translatable across histologies? #esmo22 
Radiation Oncologist at the Peter MacCallum Cancer Centre @petermaccc, Associate Professor University of Melbourne, Australia ????. Views are my own. #radonc